Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831161) titled 'Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Dong-A University Hospital
Condition:
Recurrent Glioblastoma
Intervention:
Biological: CHANK-101
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: September 29, 2026
Target Sample Size: 60
Countries of Recruitment:
South Korea
To know more, visit https://clinicaltrials.gov/study/NC...